Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

N Levitan

Showing results (21-30 of 52) with videos related to

Pageof 6
Sort By:
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk|May 25, 2004
[The role of cytokines and interferon-alpha in the pathogenesis of chronic diffuse diseases of the liver]A V Astakhin, S S Afanas'ev, A A Vorob'ev, et al.
Terapevticheskii Arkhiv|April 6, 2005
[Immunogenetic HLA markers of chronic viral hepatitis]E A Popov, B N Levitan, L P Alekseev, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 1999
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trialN Levitan, A Dowlati, M Craffey, et al.
Neurology|February 1, 1987
Motor neuron disease and paraproteinemiaS Rudnicki, D A Chad, D A Drachman, et al.
Human Pathology|October 1, 1985
Transformation of lymphoma to amyloidoma following radiation therapyN Levitan, A Rubinow, R H Bromer, et al.
The Journal of Nervous and Mental Disease|May 26, 2021
Could Dispositional Optimism Impair Panic Disorder and Depression Outcomes?Michele F Rodrigues, Ruan Vianna, Melyssa K Galdino, et al.
Gastrointestinal Endoscopy|August 26, 1998
Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiationG Isenberg, A Chak, M I Canto, et al.
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii|June 11, 2004
[Tumor necrosis factor-alpha and interleukin-4 in the blood sera of chronic hepatitis patients]A V Astakhin, B N Levitan, S S Afanas'ev, et al.
Chest|September 11, 1992
Pulmonary venous infarctionW A Williamson, B S Tronic, N Levitan, et al.
Medicine|September 28, 1999
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims dataN Levitan, A Dowlati, S C Remick, et al.
Pageof 6

Showing results (21-30 of 52) with videos related to

Sort By:
Pageof 6
Vestnik Rossiiskoi Akademii Meditsinskikh Nauk|May 25, 2004
[The role of cytokines and interferon-alpha in the pathogenesis of chronic diffuse diseases of the liver]A V Astakhin, S S Afanas'ev, A A Vorob'ev, et al.
Terapevticheskii Arkhiv|April 6, 2005
[Immunogenetic HLA markers of chronic viral hepatitis]E A Popov, B N Levitan, L P Alekseev, et al.
Lung Cancer (Amsterdam, Netherlands)|February 27, 1999
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trialN Levitan, A Dowlati, M Craffey, et al.
Neurology|February 1, 1987
Motor neuron disease and paraproteinemiaS Rudnicki, D A Chad, D A Drachman, et al.
Human Pathology|October 1, 1985
Transformation of lymphoma to amyloidoma following radiation therapyN Levitan, A Rubinow, R H Bromer, et al.
The Journal of Nervous and Mental Disease|May 26, 2021
Could Dispositional Optimism Impair Panic Disorder and Depression Outcomes?Michele F Rodrigues, Ruan Vianna, Melyssa K Galdino, et al.
Gastrointestinal Endoscopy|August 26, 1998
Endoscopic ultrasound in restaging of esophageal cancer after neoadjuvant chemoradiationG Isenberg, A Chak, M I Canto, et al.
Zhurnal Mikrobiologii, Epidemiologii I Immunobiologii|June 11, 2004
[Tumor necrosis factor-alpha and interleukin-4 in the blood sera of chronic hepatitis patients]A V Astakhin, B N Levitan, S S Afanas'ev, et al.
Chest|September 11, 1992
Pulmonary venous infarctionW A Williamson, B S Tronic, N Levitan, et al.
Medicine|September 28, 1999
Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy. Risk analysis using Medicare claims dataN Levitan, A Dowlati, S C Remick, et al.
Pageof 6